HomeCompareAITXD vs ABBV

AITXD vs ABBV: Dividend Comparison 2026

AITXD yields 4048.58% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AITXD wins by $8061531857256.32M in total portfolio value
10 years
AITXD
AITXD
● Live price
4048.58%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8061531857256.42M
Annual income
$7,687,983,219,612,022,000.00
Full AITXD calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AITXD vs ABBV

📍 AITXD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAITXDABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AITXD + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AITXD pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AITXD
Annual income on $10K today (after 15% tax)
$344,129.55/yr
After 10yr DRIP, annual income (after tax)
$6,534,785,736,670,218,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, AITXD beats the other by $6,534,785,736,670,197,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AITXD + ABBV for your $10,000?

AITXD: 50%ABBV: 50%
100% ABBV50/50100% AITXD
Portfolio after 10yr
$4030765928628.26M
Annual income
$3,843,991,609,806,023,000.00/yr
Blended yield
95.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AITXD
No analyst data
Altman Z
-15.4
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AITXD buys
0
ABBV buys
0
No recent congressional trades found for AITXD or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAITXDABBV
Forward yield4048.58%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8061531857256.42M$102.3K
Annual income after 10y$7,687,983,219,612,022,000.00$24,771.77
Total dividends collected$8036062888182.31M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AITXD vs ABBV ($10,000, DRIP)

YearAITXD PortfolioAITXD Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$415,558$404,858.30$11,550$430.00+$404.0KAITXD
2$16,168,220$15,723,572.58$13,472$627.96+$16.15MAITXD
3$589,038,841$571,738,845.21$15,906$926.08+$589.02MAITXD
4$20,097,119,938$19,466,848,378.98$19,071$1,382.55+$20097.10MAITXD
5$642,232,524,688$620,728,606,353.73$23,302$2,095.81+$642232.50MAITXD
6$19,225,768,320,335$18,538,579,518,919.37$29,150$3,237.93+$19225768.29MAITXD
7$539,233,159,841,758$518,661,587,738,999.50$37,536$5,121.41+$539233159.80MAITXD
8$14,172,417,177,673,084$13,595,437,696,642,402.00$50,079$8,338.38+$14172417177.62MAITXD
9$349,110,876,303,174,100$333,946,389,923,063,900.00$69,753$14,065.80+$349110876303.10MAITXD
10$8,061,531,857,256,418,000$7,687,983,219,612,022,000.00$102,337$24,771.77+$8061531857256.32MAITXD

AITXD vs ABBV: Complete Analysis 2026

AITXDStock

Artificial Intelligence Technology Solutions Inc. engages in the delivery of artificial intelligence and robotic solutions for operational, security, and monitoring needs in the United States. The company offers ROAMEO, an autonomous, mobile security robotic vehicle designed to patrol large outdoor spaces; RADDOG LE2, a wheeled, four-legged robotic platform developed for law enforcement and tactical applications; and HERO, a humanoid security robot. It also provides AVA, a gate security solution that manages vehicle entry using AI-powered license plate recognition, two-way voice interaction, and cloud-based authorization; TOM, an AI-powered solution that automates visitor management and front desk functions; and RADCam, an AI-powered, voice-enabled security camera designed for homeowners, property managers, and small businesses. In addition, the company provides ROSA, a compact, self-contained security device that provides autonomous deterrence, detection, and response; RAM, a hardware module that transforms existing IP security cameras into interactive devices; RIO, a portable, solar-powered security tower that includes a single or dual ROSA unit mounted atop a solar panel trailer; and RADCam, a voice-enabled security camera designed for homeowners, property managers, and small businesses. Further, it offers SARA, a voice and decision-making platform; Firearm Detection, an AI-based analytic that identifies visible handguns and guns in real time; and ROSS which enables immediate response and alert escalation the moment a threat is recognized. The company was formerly known as On The Move Systems Corp. and changed its name to Artificial Intelligence Technology Solutions Inc. in August 2018. Artificial Intelligence Technology Solutions Inc. was founded in 2016 and is based in Ferndale, Michigan.

Full AITXD Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AITXD vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AITXD vs SCHDAITXD vs JEPIAITXD vs OAITXD vs KOAITXD vs MAINAITXD vs JNJAITXD vs MRKAITXD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.